Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms - Summary - MDSpire

Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms

  • By

  • Jialai Wang

  • Ying Yang

  • Ziwei Wang

  • Chengdong Liu

  • Yanhua Han

  • Xiaoke Wu

  • Hui Chang

  • July 13, 2026

Share

Objective:

To systematically evaluate the therapeutic potential of astaxanthin for PCOS and its mechanisms of action.

Approach:
  • Literature Search: A comprehensive literature search was performed across PubMed, Web of Science, and Scopus for relevant studies published between January 2020 and March 2026.
  • Inclusion Criteria: Retrieved records were screened based on predefined inclusion and exclusion criteria.
  • Mechanistic Analysis: Included studies were subjected to mechanistic analysis to evaluate the effects of astaxanthin.
Key Findings:
  • Astaxanthin exhibits significant antioxidant, anti-inflammatory, anti-proliferative, and anti-apoptotic activities.
  • It enhances insulin sensitivity and activates the Nrf2 antioxidant pathway.
  • Astaxanthin inhibits the NF-κB inflammatory signaling pathway and modulates cellular apoptosis.
Interpretation:

Astaxanthin may serve as a potential adjuvant therapy for PCOS by improving symptoms through its antioxidant and anti-inflammatory properties.

Limitations:
  • Existing pharmacological treatments for PCOS have limitations in efficacy and safety.
  • The heterogeneity of the PCOS population complicates targeted treatment strategies.
Conclusion:

Astaxanthin shows promise as a dietary supplement for improving PCOS symptoms, warranting further investigation.

Original Source(s)

Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms

  • by Jialai Wang, Ying Yang, Ziwei Wang, Chengdong Liu, Yanhua Han, Xiaoke Wu, Hui Chang

  • July 13, 2026

Related Content

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.

First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.